A5006132935- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Head and Neck Cancer Studies
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Head and Neck Surgical Oncology
- Pelvic floor disorders treatments
- Methemoglobinemia and Tumor Lysis Syndrome
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Ferroptosis and cancer prognosis
- Sexual function and dysfunction studies
- Endometriosis Research and Treatment
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Porphyrin Metabolism and Disorders
- Neonatal Health and Biochemistry
- HER2/EGFR in Cancer Research
Astellas Pharma (United States)
2024-2025
Emory Healthcare
2020-2023
Emory University
2023
Atrium Health Wake Forest Baptist
2019-2020
Abstract Background Immune-related adverse events (irAEs) are a common phenomenon in cancer patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of these irAEs have not been illustrated clearly. In this study, we analyzed for seven FDA-approved ICIs treatment to show pattern burden among patients. Methods associated ICIs, including three PD-1 (cemiplimab, nivolumab and pembrolizumab), PD-L1 (atezolizumab, avelumab durvalumab), one CTLA-4 inhibitor...
Statin drugs, frequently used to treat hyperlipidemia, are associated with improved survival outcomes in multiple solid tumor types, including head and neck squamous cell carcinoma (HNSCC). Preclinical studies suggest that manipulation of cholesterol statins other agents can enhance the function components involved anti-tumor immune responses. Retrospective types statin therapy is responses checkpoint blockade (ICB), but this has not yet been investigated HNSCC. Pharmacy records were...
Abstract Background The purpose of this study was to provide further insights into whether age and/or sex are associated with prognosis in oral tongue squamous cell carcinoma. Methods This a retrospective cohort utilizing hospital registry data from 2006 2016 obtained the National Cancer Database. Identified patients were divided various cohorts based on age, sex, and staging. A descriptive analysis performed using chi‐square tests overall survival rates estimated Kaplan–Meier method....
Background: EGFR alterations are commonly observed in malignant gliomas (MG). Osimertinib, an irreversible EGFR-tyrosine kinase inhibitor, effectively penetrates the blood brain barrier and achieves therapeutic concentrations tissue.
<h3>Background</h3> Anti-programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) has become a common first line treatment for head and neck squamous carcinoma (HNSCC). Despite its frequent use, there is need further improvement in patient outcomes. It been previously shown that HMG-CoA Reductase inhibitors (statins) have increased response rates other solid tumors when combined with anti-PD-1 ICB.<sup>1</sup> In our preclinical studies, lovastatin or simvastatin combination...
Introduction At Wake Forest Baptist Health, an adult tumor lysis syndrome pocket card was created in order to optimize management of and outline specific recommendations for the use rasburicase. Due increased rasburicase at our institution its cost, purpose this study evaluate utilization pediatric patients inpatient outpatient settings. Methods This observational, single-center, non-randomized, retrospective chart review conducted between September 2018 August 2019. The primary objective...
Abstract EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target. Unlike other tyrosine kinase inhibitors (TKIs), osimertinib (osi), a third-generation, irreversible EGFR-TKI used to treat EGFR-mutant lung cancer, is able effectively penetrate the blood brain barrier (BBB) and achieve concentrations tissue. METHODS: A retrospective chart review identified six patients (pts) aged 46–74 years with recurrent...